CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation

Cell Reports

Volumn 12, Issue 4, 2015, Pages 622-635

  Roccaro, Aldo M ^a   Mishima, Yuji ^a,g   Sacco, Antonio ^a   Moschetta, Michele ^a   Tai, Yu Tzu ^a   Shi, Jiantao ^b,c   Zhang, Yong ^a   Reagan, Michaela R ^a,h   Huynh, Daisy ^a   Kawano, Yawara ^a   Sahin, Ilyas ^a   Chiarini, Marco ^a,d   Manier, Salomon ^a   Cea, Michele ^a   Aljawai, Yosra ^a   Glavey, Siobhan ^a   Morgan, Elizabeth ^e   Pan, Chin ^f   Michor, Franziska ^b,c   Cardarelli, Pina ^f   Kuhne, Michelle ^f   Ghobrial, Irene M ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d SPEDALI CIVILI   (Italy)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Bristol Myers Squibb   (United States)

^g CANCER CHEMOTHERAPY CENTER   (Japan)

^h Maine Medical Center Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN G4; LENALIDOMIDE; ULOCUPLUMAB; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE METASTASIS; CANCER CONTROL; CANCER INHIBITION; CANCER SURVIVAL; CELL CLONE; CELL INTERACTION; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; EXTRAMEDULLARY MYELOMA; FEMALE; GENETIC TRANSFORMATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN TARGETING; SURVIVAL TIME; TRANSCRIPTION INITIATION; TUMOR INVASION; ANIMAL; BONE TUMOR; CELL CULTURE; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; SARCOMA, MYELOID; SCID MOUSE; SECONDARY;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; CELLS, CULTURED; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICE; MICE, SCID; RECEPTORS, CXCR4; SARCOMA, MYELOID; TRANSCRIPTIONAL ACTIVATION;

EID: 84947040460     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.06.059     Document Type: Article

References (54)

1. Acloque, H., Adams, M.S., Fishwick, K., Bronner-Fraser, M., and Nieto, M.A. (2009). Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest. 119, 1438-1449.
2. Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U.K., Pitsillides, C.M., Spencer, J.A., Kimlinger, T., Ghobrial, J.M., Jia, X., et al. (2007). Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109, 2708-2717.
3. Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166-169.
4. Ansieau, S., Bastid, J., Doreau, A., Morel, A.P., Bouchet, B.P., Thomas, C., Fauvet, F., Puisieux, I., Doglioni, C., Piccinin, S., et al. (2008). Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14, 79-89.
5. Azab, A.K., Hu, J., Quang, P., Azab, F., Pitsillides, C., Awwad, R., Thompson, B., Maiso, P., Sun, J.D., Hart, C.P., et al. (2012a). Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 119, 5782-5794.
6. Azab, F., Azab, A.K., Maiso, P., Calimeri, T., Flores, L., Liu, Y., Quang, P., Roccaro, A.M., Sacco, A., Ngo, H.T., et al. (2012b). Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. Clin. Cancer Res. 18, 91-104.
7. Brabletz, T., Jung, A., Hermann, K., Günther, K., Hohenberger, W., and Kirchner, T. (1998). Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract. 194, 701-704.
8. Brabletz, T., Jung, A., Reu, S., Porzner, M., Hlubek, F., Kunz-Schughart, L.A., Knuechel, R., and Kirchner, T. (2001). Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA 98, 10356-10361.
9. Brault, L., Rovó, A., Decker, S., Dierks, C., Tzankov, A., and Schwaller, J. (2014). CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia. Leukemia 28, 566-576.
10. Burger, M., Glodek, A., Hartmann, T., Schmitt-Gräff, A., Silberstein, L.E., Fujii, N., Kipps, T.J., and Burger, J.A. (2003). Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22, 8093-8101.
11. Colmone, A., Amorim, M., Pontier, A.L., Wang, S., Jablonski, E., and Sipkins, D.A. (2008). Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322, 1861-1865.
12. Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, Dj., and Horwitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317.
13. Garayoa, M., Garcia, J.L., Santamaria, C., Garcia-Gomez, A., Blanco, J.F., Pandiella, A., Herná ndez, J.M., Sanchez-Guijo, F.M., del Cañizo, M.C., Gutié rrez, N.C., and San Miguel, J.F. (2009). Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 23, 1515-1527.
14. Ghobrial, I.M. (2012). Myeloma as a model for the process of metastasis: implications for therapy. Blood 120, 20-30.
15. Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J.A., Avet-Loiseau, H., Kyle, R.A., et al. (2005). International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412-3420.
16. Gupta, P.B., Mani, S., Yang, J., Hartwell, K., and Weinberg, R.A. (2005). The evolving portrait of cancer metastasis. Cold Spring Harb. Symp. Quant. Biol. 70, 291-297.
17. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
18. Juarez, J.G., Thien, M., Dela Pena, A., Baraz, R., Bradstock, K.F., and Bendall, L.J. (2009). CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK. Br. J. Haematol. 145, 491-499.
19. Jung, Y., Kim, J.K., Shiozawa, Y., Wang, J., Mishra, A., Joseph, J., Berry, J.E., McGee, S., Lee, E., Sun, H., et al. (2013). Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat. Commun. 4, 1795.
20. Kalluri, R., and Neilson, E.G. (2003). Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112, 1776-1784.
21. Kalluri, R., and Weinberg, R.A. (2009). The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428.
22. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., and Salzberg, S.L. (2013). TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36.
23. Kovaleva, V., Mora, R., Park, Y.J., Plass, C., Chiramel, A.I., Bartenschlager, R., Döhner, H., Stilgenbauer, S., Pscherer, A., Lichter, P., and Seiffert, M. (2012). miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res. 72, 1763-1772.
24. Kuhne, M.R., Mulvey, T., Belanger, B., Chen, S., Pan, C., Chong, C., Cao, F., Niekro, W., Kempe, T., Henning, K.A., et al. (2013). BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin. Cancer Res. 19, 357-366.
25. Kyle, R.A., and Rajkumar, S.V. (2008). Multiple myeloma. Blood 111, 2962-2972.
26. Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408.
27. Medici, D., Hay, E.D., and Goodenough, D.A. (2006). Cooperation between snail and LEF-1 transcription factors is essential for TGF-beta1-induced epithelial-mesenchymal transition. Mol. Biol. Cell 17, 1871-1879.
28. Medici, D., Hay, E.D., and Olsen, B.R. (2008). Snail and Slug promote epithelial- mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol. Biol. Cell 19, 4875-4887.
29. Möller, C., Strömberg, T., Juremalm, M., Nilsson, K., and Nilsson, G. (2003). Expression and function of chemokine receptors in human multiple myeloma. Leukemia 17, 203-210.
30. Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56.
31. Okada, H., Danoff, T.M., Kalluri, R., and Neilson, E.G. (1997). Early role of Fsp1 in epithelial-mesenchymal transformation. Am. J. Physiol. 273, F563- F574.
32. Orimo, A., Gupta, P.B., Sgroi, D.C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V.J., Richardson, A.L., and Weinberg, R.A. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348.
33. Oriol, A. (2011). Multiple myeloma with extramedullary disease. Adv. Ther. 28 (Suppl 7), 1-6.
34. Roccaro, A.M., Sacco, A., Thompson, B., Leleu, X., Azab, A.K., Azab, F., Runnels, J., Jia, X., Ngo, H.T., Melhem, M.R., et al. (2009). MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 113, 6669-6680.
35. Roccaro, A.M., Sacco, A., Husu, E.N., Pitsillides, C., Vesole, S., Azab, A.K., Azab, F., Melhem, M., Ngo, H.T., Quang, P., et al. (2010). Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115, 559-569.
36. Roccaro, A.M., Sacco, A., Maiso, P., Azab, A.K., Tai, Y.T., Reagan, M., Azab, F., Flores, L.M., Campigotto, F., Weller, E., et al. (2013). BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123, 1542-1555.
37. Roccaro, A.M., Sacco, A., Purschke, W.G., Moschetta, M., Buchner, K., Maasch, C., Zboralski, D., Zöllner, S., Vonhoff, S., Mishima, Y., et al. (2014). SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep. 9, 118-128.
38. Sacco, A., Aujay, M., Morgan, B., Azab, A.K., Maiso, P., Liu, Y., Zhang, Y., Azab, F., Ngo, H.T., Issa, G.C., et al. (2011). Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin. Cancer Res. 17, 1753-1764.
39. Schioppa, T., Uranchimeg, B., Saccani, A., Biswas, S.K., Doni, A., Rapisarda, A., Bernasconi, S., Saccani, S., Nebuloni, M., Vago, L., et al. (2003). Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. 198, 1391-1402.
40. Smit, M.A., and Peeper, D.S. (2008). Deregulating EMT and senescence: double impact by a single twist. Cancer Cell 14, 5-7.
41. Stessman, H.A., Mansoor, A., Zhan, F., Janz, S., Linden, M.A., Baughn, L.B., and Van Ness, B. (2013). Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia 27, 2075-2077.
42. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550.
43. Susaki, E.A., Tainaka, K., Perrin, D., Kishino, F., Tawara, T., Watanabe, T.M., Yokoyama, C., Onoe, H., Eguchi, M., Yamaguchi, S., et al. (2014). Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. Cell 157, 726-739.
44. Thiery, J.P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442-454.
45. Varettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C., and Lazzarino, M. (2010). Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann. Oncol. 21, 325-330.
46. Vićovac, L., and Aplin, J.D. (1996). Epithelial-mesenchymal transition during trophoblast differentiation. Acta Anat. (Basel) 156, 202-216.
47. Weinstock, M., and Ghobrial, I.M. (2013). Extramedullary multiple myeloma. Leuk. Lymphoma 54, 1135-1141.
48. Weinstock, M., Aljawai, Y., Morgan, E.A., Laubach, J., Gannon, M., Roccaro, A.M., Varga, C., Mitsiades, C.S., Paba-Prada, C., Schlossman, R., et al. (2015). Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br. J. Haematol. 169, 851-858.
49. Yagi, H., Tan, W., Dillenburg-Pilla, P., Armando, S., Amornphimoltham, P., Simaan, M., Weigert, R., Molinolo, A.A., Bouvier, M., and Gutkind, J.S. (2011). A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci. Signal. 4, ra60.
50. Yang, J., and Weinberg, R.A. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14, 818-829.
51. Yang, J., Mani, S.A., and Weinberg, R.A. (2006). Exploring a new twist on tumor metastasis. Cancer Res. 66, 4549-4552.
52. Zeisberg, E.M., Tarnavski, O., Zeisberg, M., Dorfman, A.L., McMullen, J.R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W.T., Roberts, A.B., et al. (2007a). Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13, 952-961.
53. Zeisberg, M., Yang, C., Martino, M., Duncan, M.B., Rieder, F., Tanjore, H., and Kalluri, R. (2007b). Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 282, 23337-23347.
54. Zhang, Y., Moschetta, M., Huynh, D., Tai, Y.T., Zhang, Y., Zhang, W., Mishima, Y., Ring, J.E., Tam, W.F., Xu, Q., et al. (2014). Pyk2 promotes tumor progression in multiple myeloma. Blood 124, 2675-2686.